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A B S T R A C T
The paper describe the use of rFVIIa in the management of massive bleeding in a patient with polytrauma involving
liver injury. An 18-year-old girl with severe polytrauma sustained during a bus–car collision. She had multiple mus-
culoskeletal injuries, severe concussion of the liver with amputation of the left liver lobe, disruption of the left hepatic
vein from the inferior vena cava, and impaired hemostasis. Acute bleeding (>5 L) was not improved by conservative
methods and a single dose of rFVIIa 90 g/kg was administered. Infusion of rFVIIa resulted in an immediate clinical ef-
fect with rapid improvements in blood laboratory measurements and coagulation parameters. rFVIIa should be consid-
ered as an adjunctive treatment for the control of hemorrhage in severely injured patients with uncontrolled bleeding
and impaired hemostasis.
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Introduction
Polytrauma is a life-threatening condition character-
ized by severe blunt trauma with injuries to multiple or-
gan systems, generally including musculoskeletal and
abdominal organ injuries, and extensive soft tissue in-
jury. Individuals with polytrauma are at a high risk of
systemic soft tissue inflammation, contusions and ede-
ma1, and most require massive blood volume replace-
ment together with implementation of treatment strate-
gies for adequate and safe bleeding control2,3.
Surgery followed by blood-product transfusion suc-
cessfully manages hemorrhage and hemostatic instabil-
ity in many polytrauma patients, but some patients con-
tinue to bleed uncontrollably. Persistent blood loss is a
major cause of trauma-related deaths and the mortality
risk is further increased by the inevitable consequences
of hemodilution, hypothermia, acidosis and coagulopa-
thy4. Initial treatment for intractable hemorrhage in-
volves blood-component therapy (e.g. packed red blood
cells PRBC, fresh frozen plasma FFP). Massive blood
transfusion may be required in the most severe cases,
but this is associated with serious complications such as
infection and multiple organ failure4–8. In recent years, a
number of pharmacotherapies have become available
(e.g. desmopressin, tranexamic acid, aprotinin) to be
used when surgery is insufficient to curb the bleeding
and also to reduce transfusion requirements9.
Recombinant factor VIIa (rFVIIa, Novo Nordisk, Bag-
svaerd, Denmark) is a hemostatic agent that is approved
in over 50 countries worldwide for the management of
spontaneous or surgical hemorrhage in patients with
bleeding disorders. Evidence from investigational research
has indicated that rFVIIa may also be effective in intrac-
table bleeding episodes of varying etiology in non-hemo-
philia patients10. Indeed, effective use of rFVIIa in a
trauma situation was first reported in 1999 when bleed-
ing was stopped in a patient with a serious rifle injury
following unsuccessful surgical intervention and blood-
-product transfusion11. Successful hemorrhage control
with adjunctive rFVIIa in patients with severe trauma
has since been demonstrated in a number of case re-
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ports12–20, as well as two randomized, placebo-controlled,
double-blind clinical trials21. The present case report de-
scribes the use of rFVIIa in the management of massive
bleeding in a female patient with polytrauma involving
liver injury.
Case Report
An 18-year-old girl sustained severe polytrauma as a
passenger on a bus involved in a bus–car collision, and
was transferred by ambulance to the University Hospital
of Traumatology in Zagreb. On admission, the patient
was somnolent and amnestic of the event, with a Glas-
gow Coma Score (GCS) of 13, Trauma Score (TS) of 12,
and she was hemodynamically unstable (tachycardia,
120 beats/min; blood pressure, 90/60 mmHg). She com-
plained of pain in the abdomen, back and right he-
mithorax. Clinical examination revealed right thorax de-
formity and, on auscultation, there was shallow breathing
on the right side with subcutaneous emphysema. Neuro-
logical status was normal with preserved motoricity of all
four extremities. Peripheral venous lines were inserted
for volume replacement with crystalloid and colloid infu-
sions and analgesia was administered with morphine at a
dose of 0.1 mg/kg. Emergency diagnostic assessments
were conducted, including x-ray, ultrasonography and
computed tomography (CT).
The patient was found to have multiple musculo-
skeletal injuries. Intrathoracic x-ray revealed fracture
and cranial dislocation of the seventh and eighth ribs on
the right, along with pleural effusion.The right side of
the thorax was distorted, with a visible gap of approxi-
mately 10 cm between the inferior ribs. X-ray of the spine
showed T6 fracture without fracture fragment migration
to the spinal canal.The patient remained free from neu-
rological deficit and brain CT was normal but had a se-
verely painful, tight and distended abdomen. After ad-
mission to the intensive care unit, abdominal ultraso-
nography and CT scan revealed a large amount of free
intraperitoneal fluid on the right, along the lateral liver
margin and left liver lobe. Extensive free fluid was also
observed in the pelvis minor, close to the bladder. Labora-
tory test results of slightly lower hemoglobin (98 g/L;
normal range, 115–165 g/L) and hematocrit level (0.31;
normal range, 0.36–0.47), normal prothrombin time (PT
14.6 s; normal range is usually within the range of 10–15
seconds), metabolic acidosis (with base excess of –8
mmol/L) and increased lactate levels (3.0 mmol/L; nor-
mal range, 0.5–2.2 mmol/L, Table 1).
Emergency laparotomy revealed severe concussion of
the liver with amputation of the left liver lobe and dis-
ruption of the left hepatic vein from the inferior vena
cava. Acute blood loss was estimated to be approximately
5 L, so replacement therapy with 4.5 L of crystalloids and
1 L of colloids plus 7.5% NaCl (4 mL/kg) was adminis-
tered. The patient’s marked hemodynamic instability
continued, indicated by a second laboratory assessment
(reduced hemoglobin 35 g/L, hematocrit 0.11 and plate-
lets 117 x 109/L, prolonged PT 18.9 s and aPTT 38.2 s,
low fibrinogen 0.7 g/L, Table 1) as well as systolic blood
pressure of approximately 60 mmHg and tachycardia of
140 beats/min. Consequently, inotropic support with no-
repinephrine (0.02–0.04 g/kg/min) was introduced in-
traoperatively and, prior to ligature of the blood vessels,
a single dose of rFVIIa 90 g/kg was administered. An
immediate clinical effect of the rFVIIa was observed, and
resection of the left liver lobe and suture of the inferior
vena cava were performed. During the 3-hour surgical
procedure, blood loss exceeded one circulating blood vol-
ume so massive blood transfusion was required (15 units
of PRBC; 8 units of FFP, 15 mL/kg and 8 units of plate-
lets).
Laboratory assessment 6 hours after surgery showed
that blood counts had near-normalized following the ad-
ministration of rFVIIa: hemoglobin increased to 110 g/L
and hematocrit to 0.32 (Table 1). Similarly, improve-
ments in coagulation parameters meant that they were
close to or within the reference ranges (PT of 12.6 s;
aPTT of 24 s; fibrinogen of 2 g/L). Metabolic acidosis was
corrected, while the level of lactate decreased from 3
mmol/L to 1.2 mmol/L within 24 hours of trauma.
Postoperatively, the patient was connected to a me-
chanical respiratory device, extubated within 24 hours of
the injury and the right hemithorax was drained. Coagu-
lation factors were found to be within or close to their
reference ranges 4 days after rFVIIa administration (Ta-
ble 2). Posterior spondylosis of the thoracic spine was
identified 12 days after the injury and corrected with sur-
gical intervention. The patient was discharged from hos-
pital in good general condition 20 days after admission.
A CT scan of the abdomen was performed on the eight
postoperative day after liver resection. It shows the con-
dition after resection of the left liver lobe with signs of
pancreatic contusion and low level of ascites.
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TABLE 1
LABORATORY PARAMETERS BEFORE AND AFTER rFVIIa ADMINISTRATION



































aPTT – activated partial thromboplastin time, PT – prothrombin time
Discussion
In this case study, adjunctive treatment with a single
dose of rFVIIa (90 g/kg) proved useful in the control of
severe hemorrhage due to polytrauma and involving
blunt liver injury. The liver plays a crucial role in the reg-
ulation of coagulation factors and injury may impair
hemostasis resulting in massive bleeding, as seen in this
patient6,22. Blunt liver trauma is a major cause of death
in patients with abdominal injury, with reported mortal-
ity rates of 11–21% potentially increasing to 50–67% in
severe cases; most deaths are attributed to exsanguina-
tions13,23–28. As blood loss is usually severe in patients
with polytrauma involving the liver, frequently exceed-
ing one circulating blood volume, replacement therapy
with high volumes of crystalloids and colloids, as well as
transfusion of multiple blood products, is generally nec-
essary in order to maintain normovolemia and to prevent
hypoxemia29. However, such treatment causes dilution of
coagulation factors and platelets, and ultimately leads to
consumption coagulopathy.
The present case illustrates the typical clinical pic-
ture of polytrauma with liver injury. Despite the severity
of the situation, treatment with rFVIIa in conjunction
with surgical intervention led to hemorrhage control
with rapid improvements in blood laboratory measure-
ments and coagulation parameters.
The mechanism of action of rFVIIa in non-hemophilia
patients is yet to be established; pharmacological doses
directly activate factor IX on the surfaces of activated
platelets, in the absence of tissue factor, leading to forma-
tion of additional tenase complexes, and improved throm-
bin generation, clot structure and clot stability at the site
of injury30.
The effectiveness of rFVIIa in our case patient adds to
the evidence of its beneficial effects in blunt trauma inju-
ries shown in clinical trials21 and case reports13,14,17–20.
Conclusion
This report indicates that rFVIIa may be useful as an
adjunctive treatment for the control of hemorrhage in
traumatized patients and may reduce the need to admin-
ister blood products; in many cases, coagulation parame-
ters are normalized. Although associated with additional
costs, early hemorrhage control through rFVIIa adminis-
tration can reduce the risk of infection transmission and
costs associated with blood product transfusion. Investi-
gations to determine the optimal therapeutic use of rFVIIa
in non-hemophilia patients with uncontrolled bleeding
are warranted.
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USPIJE[NA PRIMJENA AKTIVIRANOG REKOMBINANTNOG FAKTORA VIIa KOD TRAUMATSKE
OZLIJEDE JETRE: PRIKAZ SLU^AJA
S A @ E T A K
Aktivirani rFVIIa je dobro hemostatsko sredstvo u zbrinjavanju krvarenja kod bolesnika sa hemofilijom i inhibi-
torima faktora VIII ili IX. Tako|er se uspje{no upotrebljava u kontroli krvarenja u kirur{kih bolesnika u traumi i
»non-hemophilia« koagulopatija kod kojih je ugro`en `ivot zbog nekontrolibilnog krvarenja. Politrauma u okviru te{kih
ozljeda lokomotornog sustava sa pridru`enim o{te}enjem abdominalnih organa je za `ivot opasno stanje, koje zahtjeva
veliku nadoknadu volumena i krvnih pripravaka, te adekvatnu i sigurnu kontrolu krvarenja. Donosimo vam prikaz
slu~aja primjene rFVIIa u zbrinjavanju masivnog krvarenja kod politraumatizirane bolesnice sa dominantnom ozlije-
dom jetre.
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